Skip to main content
. Author manuscript; available in PMC: 2021 Mar 22.
Published in final edited form as: Chem Biol Drug Des. 2017 Nov 3;91(2):491–504. doi: 10.1111/cbdd.13110

FIGURE 2.

FIGURE 2

(a) Refined FGF23 models with possible binding sites (spheres) that were used as the center of search boxes in the in silico screening campaign. The areas predicted to form protein–protein interactions with FGFR are shown in cyan, orange, yellow, and gray surf. (b) Side-chain variability captured in the ensemble of Arg140